Clavudale 500mg

Main information

  • Trade name:
  • Clavudale 500mg
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Clavudale 500mg
    Portugal
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • amoxicillin and enzyme inhibitor
  • Therapeutic area:
  • Cats, Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0373/003
  • Authorization date:
  • 01-05-2012
  • EU code:
  • UK/V/0373/003
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:March2011

AN:01855/2009

1.NAMEOFTHEVETERINARYMEDICINALPRODUCT

Clavudale500mgtabletfordogs(UK,Ireland,France,Austria,Belgium,CzechRepublic,

Greece,Hungary,Iceland,Luxembourg,Norway,Poland,Portugal,SlovakRepublic)

Clavudale400mg/100mgtabletfordogs(Germany,Netherlands,Denmark,Spain,Finland,

Sweden)

2.QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

ActiveSubstances:

Amoxicillin(asamoxicillintrihydrate) 400mg

Clavulanicacid(aspotassiumclavulanate) 100mg

Excipients:

Erythrosine(E127)7.5mg

Forafulllistofexcipientsseesection6.1.

3.PHARMACEUTICALFORM

Tablet.

Pinkoblongscoredtablets.

Thetabletcanbedividedintoequalhalves.

4.CLINICALPARTICULARS

4.1Targetspecies

Dogs

4.2Indicationsforuse,specifyingthetargetspecies

Forthetreatmentofbacterialinfectionssusceptibletoamoxicillinincombinationwith

clavulanicacidwhereclinicalexperienceand/orsensitivitytestingindicatestheproductasthe

drugofchoice.

Usesinclude:

Skininfections(includingdeepandsuperficialpyodermas)associatedwithStaphylococci

andStreptococci;

Infectionsoftheoralcavity(mucousmembrane)associatedwithClostridia,Corynebacteria,

Staphylococci,Streptococci,Bacteroidesspp.andPasteurellae.;

UrinarytractinfectionsassociatedwithStaphylococci,Streptococci,Escherichiacoliand

Proteusspp;

RespiratorytractinfectionsassociatedwithStaphylococci,StreptococciandPasteurellae;

GastrointestinalinfectionsassociatedwithEscherichiacoliandProteusspp.

Revised:March2011

AN:01855/2009

4.3Contraindications

Donotuseinrabbits,guineapigs,hamstersandgerbils.

Donotuseinanimalswithknownhypersensitivitytopenicillinorsubstancesoftheβ-lactam

group.

Donotuseinanimalswitheitheroliguriaoranuriaassociatedwithrenaldysfunction.

Donotuseincasesofknownresistancetothecombinationofamoxicillinandclavulanicacid.

4.4Specialwarningsforeachtargetspecies

Noneknown.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Cautionisadvisedontheuseoftheproductinsmallherbivoresotherthanthoselistedin4.3.

Inanimalswithhepaticandrenaldysfunction,thedosingregimenshouldbecarefully

evaluated.

Useoftheproductshouldbebasedonsusceptibilitytestingandshouldtakeintoaccount

officialnationalandregionalpolicieswithrespecttotheuseofbroadspectrumantibiotics.Do

notuseincasesofbacteriasensitivetonarrowspectrumpenicillinsortoamoxicillinasa

singlesubstance.UseoftheproductdeviatingfromtheinstructionsgivenintheSPCmay

increasetheprevalenceofbacteriaresistanttoamoxicillinandclavulanicacid,andmay

decreasetheeffectivenessoftreatmentwithotherβ-lactams,duetothepotentialforcross

resistance.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Penicillinsandcephalosporinsmaycausehypersensitivity(allergy)followinginjection,

inhalation,ingestionorskincontact.Hypersensitivitytopenicillinsmayleadtocross-reactions

tocephalosporinsandviceversa.Allergicreactionstothesesubstancesmayoccasionallybe

serious.

Donothandlethisproductifyouknowyouaresensitised,orifyouhavebeenadvised

nottoworkwithsuchpreparations.

Handlethisproductwithgreatcaretoavoidexposure,takingallrecommended

precautions.

Ifyoudevelopsymptomsfollowingexposuresuchasaskinrash,youshouldseek

medicaladviceandshowthedoctorthiswarning.Swellingoftheface,lipsoreyesor

difficultywithbreathingaremoreserioussymptomsandrequireurgentmedical

attention.

Washhandsafteruse.

Revised:March2011

AN:01855/2009

4.6Adversereactions(frequencyandseriousness)

Mildgastrointestinalsigns(diarrhoea,andvomiting)mayoccurafteradministrationofthe

product.

Allergicreactions(skinreactions,anaphylaxis),blooddyscrasiaandcolitismayoccasionally

occur.Inthesecases,discontinueadministrationandgivesymptomatictreatment.

4.7Useduringpregnancy,lactationorlay

Laboratorystudiesinratsandmicehavenotproducedanyevidenceofteratogenicor

foetotoxiceffects.Nostudieshavebeenconductedinpregnantorlactatingdogs.Useonly

accordingtothebenefit/riskassessmentbytheresponsibleveterinarian.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Bacteriostaticantibiotics(e.g.chloramphenicol,macrolides,sulfonamidesandtetracyclines)

mayinhibittheantibacterialeffectsofpenicillins.

Thepotentialforallergiccross-reactivitywithotherpenicillinsshouldbeconsidered.

Penicillinsmayincreasetheeffectofaminoglycosides.

4.9Amountstobeadministeredandadministrationroute

Fororaladministrationonly.Thedosagerateis10mgamoxicillin/2.5mgclavulanicacid/kg

bodyweighttwicedaily.Thetabletsmaybeaddedtoalittlefood.

Toensureacorrectdosage,bodyweightshouldbedeterminedasaccuratelyaspossibleto

avoidunder-dosing.

Thefollowingtableisintendedasaguidetodispensingtheproductatthestandarddoserate

of10mgamoxicillin/2.5mgclavulanicacid/kgtwicedaily.

Bodyweight

(kg) Numberoftabletstwice

daily

>30to≤40 1

>40to≤60

>60to≤80 2

Inrefractorycasesthedosemaybedoubledto20mgamoxicillin/5mgclavulanicacid/kg

bodyweighttwicedaily.

Durationoftherapy:

Routinecasesinvolvingallindications:

Themajorityofroutinecasesrespondtobetween5and7daysoftherapy.Lackofeffectafter

5-7daysoftreatmentnecessitatesrenewedexamination.

Chronicorrefractorycases:

Inchroniccases,longercoursesofantibacterialtherapymayberequired.Insuch

circumstances overalltreatmentlengthisattheclinician’sdiscretion,butmustbelongenough

toensurecompleteresolutionofthebacterialdisease.

Revised:March2011

AN:01855/2009

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Mildgastrointestinalsymptoms(diarrhoea,andvomiting)mayoccurmorefrequentlyafter

overdoseoftheproduct.

4.11Withdrawalperiod

Notapplicable

5. PHARMACOLOGICALPROPERTIES

ATCvetcode:QJ01CR02

Pharmacotherapeuticgroup:Beta-lactamantibacterials,penicillins.

5.1Pharmacodynamicproperties

Amoxicillinisanaminobenzylpenicillinfromtheβ-lactampenicillinfamilywhichprevents

bacterialcellwallformationbyinterferingwiththefinalstepofpeptidoglycansynthesis.

Clavulanicacidisanirreversibleinhibitorofintracellularandextr acellularβ-lactamaseswhich

protectsamoxicillinfrominactivationbymanyβ-lactamases.

Amoxicillinincombinationwithclavulanicacidhasawiderangeofactivitywhichincludes

β-lactamaseproducingstrainsofbothGram-positiveandGram-negativeaerobes,facultative

anaerobesandobligateanaerobes,including:

Gram-positiveswithgoodsusceptibility:Clostridiumspp.Corynebacteriumspp.

Staphylococcusspp.Streptococcusspp..

Gram-negativeswithgoodsusceptibility:Pasteurellaspp.Bacteroidesspp.Proteus

mirabilis.

Gram-negativeswithvariablesusceptibility:Escherichiacoli,Klebsiellaspp.

Bordetellabronchiseptica.

ResistantbacterialspeciesincludePseudomonasaeruginosa,Enterobacterspp.and

methicillin-resistantStaphylococcusaureus.

Susceptibilityandresistancepatternscanvarywithgeographicalareaandbacterialstrain,

andmaychangeovertime.

Revised:March2011

AN:01855/2009

5.2Pharmacokineticparticulars

Aftertheoraladministrationtodogsoftherecommendeddoseof10mgamoxicillin/2.5mg

clavulanicacid/kgweightthefollowingparameterswereobserved:medianT

of1.5hours

foramoxicillinandof1.0hoursforclavulanicacid.

Amoxicilliniswell-absorbedfollowingoraladministration.Indogsthesystemicbioavailability

is60-70%.Amoxicillin(pKa2.8)hasarelativelysmallapparentdistributionvolume,alow

plasmaproteinbinding(34%indogs)andashortterminalhalf-lifeduetoactivetubular

excretionviathekidneys.Followingabsorptionthehighestconcentrationsarefoundinthe

kidneys(urine)andthebileandtheninliver,lungs,heartandspleen.Thedistributionof

amoxicillintothecerebrospinalfluidislowunlessthemeningesareinflamed.

Clavulanicacid(pKa2.7)isalsowell-absorbedfollowingoraladministration.Thepenetration

tothecerebrospinalfluidispoor.Theplasmaproteinbindingisapproximately25%andthe

eliminationhalf-lifeisshort.Clavulanicacidismainlyeliminatedbyrenalexcretion

(unchangedinurine).

6.PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Erythrosine(E127)

Silica,ColloidalAnhydrous

MagnesiumStearate

SodiumStarchGlycolate(TypeA)

Cellulose,Microcrystalline

6.2Incompatibilities

Notapplicable

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:4years

Shelflifeafterfirstopeningtheimmediatepackaging:12hours

Anydividedtabletportionsremainingafter12hoursshouldbediscarded.

6.4.Specialprecautionsforstorage

Donotstoreabove25ºC.

Dividedtabletsshouldbestoredintheblisterpack.

Revised:March2011

AN:01855/2009

6.5 Natureandcompositionofimmediatepackaging

BlisterpacksconsistingoforientatedPolyamide/Aluminium/Polyvinylchloridefilm,heat

sealedwithaluminiumfoil(20µm)instripsof6tablets.Cartonscontaining12or24tablets.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

7.MARKETINGAUTHORISATIONHOLDER

DechraLimited,

DechraHouse,

JamageIndustrialEstate,

TalkePits,

Stoke-on-Trent,

Staffordshire,

ST71XW,

UK.

Tel:01782771100

Fax:01782773366

8.MARKETINGAUTHORISATIONNUMBER

Vm10434/4053

9.DATEOFFIRSTAUTHORISATION

8January2010

10.DATEOFREVISIONOFTHETEXT

March2011

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The product Bergazym® P100 contains a xylanase which is produced by a non‐genetically modified strain of Trichoderma reesei. The additive is available in a coated granular form and it is intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens for fattening, and weaned piglets at the dose of 1,500 EPU/kg feed. The production strain and the additive were fully characterised in a previous assessment of the Panel o...

Europe - EFSA - European Food Safety Authority Publications

24-10-2018

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Published on: Tue, 23 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for sows in order to have benefit in piglets. The additive HOSTAZYM® X contains endo‐1,4‐beta‐xylanase and is available in liquid and solid formulations. This product is authorised as a feed additive for chickens for fattening, tu...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

22-6-2018

Metronidazole intravenous infusion 500 mg/100 mL bag

Metronidazole intravenous infusion 500 mg/100 mL bag

Shortage and althernative supply of Metronidazole intravenous infusion 500 mg/100 mL bag

Therapeutic Goods Administration - Australia

30-10-2018

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Active substance: Glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine) - Orphan designation - Commission Decision (2018)7277 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/18

Europe -DG Health and Food Safety

29-5-2018

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Active substance: (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine) - Transfer of orphan designation - Commission Decision (2018)3402 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/185/14/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Active substance: 4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid) - Transfer of orphan designation - Commission Decision (2018)3149 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/14/T/01

Europe -DG Health and Food Safety